ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

8 links0 made here, not in the record16 judgments2 judges (our rules as one)1 record change seen
Model not recordedOur rulesRecord updated on ClinicalTrials.gov
Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04956692Study of Pembrolizumab(MK-3475) Subcutaneous (SC)Versus PembrolizumabIntravenous (IV)Administered With PlatinumDoublet Chemotherapy inParticipants WithMerck Sharp & Dohme LLCPhase 3 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 7 · ClinicalTrials.gov record · Version of 2026-10-07Version of 2026-10-07CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Nov 14 · Our condition-kind rule · Finest filed termAs of now · Our main-condition rule (R9) · Main conditionMain conditionParkinson Disease 4, Autoso…The registry's MeSH filing›Nov 14 · Our condition-kind rule · MisfiledMisfiledDRUGSPembrolizumabEntry “Pembrolizumab SC”, read by our…›Nov 1 · A model not recorded · TestedNov 18 · Our role rule · TestedNov 18 · Our role rule · ComparatorComparatorPaclitaxelIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Our role rule · BackgroundBackgroundAlbumin-Bound PaclitaxelEntry “Nab-Paclitaxel”, read by our n…›Nov 1 · A model not recorded · BackgroundNov 18 · Our role rule · BackgroundBackgroundCarboplatinIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Our role rule · BackgroundBackgroundCisplatinIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Our role rule · BackgroundBackgroundPemetrexedIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Our role rule · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pembrolizumab

From the registry record3 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Pembrolizumab SC”the record gives no role
→judged=agrees→changed
How the 3 judgments split33%of judgments with a known value say Comparator
Comparator · 1
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 7The record itselfClinicalTrials.gov recordVersion of 2026-10-07Record change
Nov 1PembrolizumabA model not recordedTestedCurrent
Nov 1PaclitaxelA model not recordedBackgroundCurrent
Nov 1Albumin-Bound PaclitaxelA model not recordedBackgroundCurrent
Nov 1CarboplatinA model not recordedBackgroundCurrent
Nov 1CisplatinA model not recordedBackgroundCurrent
Nov 1PemetrexedA model not recordedBackgroundCurrent
Nov 14Carcinoma, Non-Small-Cell LungOur condition-kind ruleFinest filed termCurrent
Nov 14Parkinson Disease 4, Autosomal Dominant Lewy BodyOur condition-kind ruleMisfiledCurrent
Nov 18PembrolizumabOur role ruleTestedAgrees
Nov 18PembrolizumabOur role ruleComparatorCurrent
Nov 18PaclitaxelOur role ruleBackgroundAgrees
Nov 18Albumin-Bound PaclitaxelOur role ruleBackgroundAgrees
Nov 18CarboplatinOur role ruleBackgroundAgrees
Nov 18CisplatinOur role ruleBackgroundAgrees
Nov 18PemetrexedOur role ruleBackgroundAgrees
As of nowCarcinoma, Non-Small-Cell LungOur main-condition rule (R9)Main conditionCurrent